(Reuters) – A costly new Roche Holding AG drug to treat the bleeding disorder hemophilia A could significantly reduce healthcare expenses for certain patients, a draft report from an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.
Novartis says it will scale up the use of Apple ResearchKit in clinical trials, as part of its efforts to bring about digital transformation.
The post Novartis and Apple to scale up clinical trial collaboration appeared first on Pharmaphorum. https://pharmaphorum.com/news/researchkit-novartis-apple-scale-clinical-trial-collaboration/
France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases. The deal announced Monday is the latest such move in a pharmaceutical industry that’s seeing increasing interest in rare diseases. http://www.topix.com/business/pharmaceuticals/2018/01/frances-sanofi-buys-us-hemophilia-specialist-bioverativ?fromrss=1
When Spark Therapeutics announced last week an $850,000 price for its gene therapy Luxturna, some critics held it up as the latest example of an expensive new treatment that could break the bank for the healthcare system. But at the J.P. Morgan Healthcare conference this week, it was clear that sentiment is rapidly changing. https://www.fiercepharma.com/financials/payers-point-to-spark-s-gene-therapy-as-a-model-for-innovative-pricing-plans
Regulatory changes and promising starts ups are fueling demand for outsourced services in China â and as venture capital flows into the country, the pace of innovation is expected to accelerate, says STA Pharmaceutical. https://www.outsourcing-pharma.com/Article/2017/12/07/Chinese-R-D-sector-takes-significant-step-as-outsourcing-demand-increases
“We are trying to do whatever we can to increase competition and give the (health insurance) plans more tools so that they can be better negotiators on our behalf,” Centers for Medicare and Medicaid Services chief Seema Verma tells Reuters. In other CMS news: The agency officially ends two mandatory bundled-payment models and Verma also comments on 1332 waivers. https://khn.org/morning-breakout/cms-considers-alternate-payment-models-to-curb-costs-on-high-price-treatments-gene-therapy/
The conversations may be about Amazon taking a role in drug purchasing, competing against distributors like McKesson, AmerisourceBergen, and Cardinal Health. https://www.biospace.com/article/around-the-web/amazon-in-exploratory-talks-with-mylan-novartis-about-pharma-entry-/
The rise of wearable technology for clinical trials
The post The rise of wearable technology for clinical trials: insights from Novartis appeared first on Pharmaphorum. https://pharmaphorum.com/partner-content/the-rise-of-wearable-technology-for-clinical-trials-insights-from-novartis/
Congress hasn’t made any progress on drug pricing legislation, but that hasn’t stopped the government from acting. Now, FDA Commissioner Scott Gottlieb has unveiled yet another move to step up competition in the generics business. http://www.fiercepharma.com/regulatory/fda-advances-price-competition-push-by-prioritizing-certain-generic-applications